Cancer is a major cause of morbidity and mortality, with an estimated 18.1 million newly diagnosed patients per year and 9.6 million cancer-related deaths in 2018 (WHO, International Agency for Research on Cancer, September 12th, 2018). Although new therapies have seen substantial success in treating this widespread disease, difficult issues remain, such as the development of resistance mechanisms, off-target cytotoxicity and lack of efficacy.
In an effort to contribute to the global combat against cancer, OncoOne aims to develop first-in-class drugs and novel, highly potent therapeutics in order to treat underserved patients suffering from solid tumor cancers.
As a business model, OncoOne intends to license drug candidates to pharmaceutical companies, taking advantage of well-established production processes and commercialization routes. Revenues will be invested in future research projects.
As an organization, we strive to apply state-of-the-art technologies and the highest possible quality standards in order to establish a successful and continuously evolving life science company.